Published in Clin Cancer Res on May 15, 2005
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell (2009) 2.13
A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst (2012) 2.07
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol (2014) 1.71
curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford) (2013) 1.40
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One (2012) 1.31
Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics (2010) 1.24
Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC Cancer (2010) 1.21
Development of a clinical decision model for thyroid nodules. BMC Surg (2009) 1.21
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res (2009) 1.16
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res (2006) 1.16
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes (2012) 1.13
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res (2010) 1.08
Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One (2011) 1.08
SlimPLS: a method for feature selection in gene expression-based disease classification. PLoS One (2009) 1.07
Prospective health care: the second transformation of medicine. Genome Biol (2006) 1.07
Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer (2011) 1.06
Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res (2009) 1.03
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol Oncol (2012) 1.03
The oncogenic role of Yin Yang 1. Crit Rev Oncog (2011) 1.02
Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer (2010) 1.02
Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun (2014) 1.02
Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet (2011) 0.99
Biomarkers for type 1 diabetes. Int J Clin Exp Med (2008) 0.98
Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw (2008) 0.98
Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol (2015) 0.97
Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Inform (2011) 0.96
A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer (2011) 0.96
Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res (2009) 0.95
Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One (2011) 0.94
Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? Eur Radiol (2008) 0.94
Pathway index models for construction of patient-specific risk profiles. Stat Med (2012) 0.93
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy. FEBS Lett (2012) 0.92
Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. J Transl Med (2012) 0.90
Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol (2007) 0.88
Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Mol Cancer (2014) 0.88
Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival. Br J Cancer (2012) 0.88
Knowledge boosting: a graph-based integration approach with multi-omics data and genomic knowledge for cancer clinical outcome prediction. J Am Med Inform Assoc (2014) 0.87
Bayesian Weibull tree models for survival analysis of clinico-genomic data. Stat Methodol (2008) 0.87
Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma. Oncotarget (2016) 0.87
Intra-relation reconstruction from inter-relation: miRNA to gene expression. BMC Syst Biol (2013) 0.86
Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. BMC Cancer (2008) 0.86
Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects. Crit Rev Oncog (2011) 0.86
Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum Mol Genet (2011) 0.85
Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. J Natl Cancer Inst (2012) 0.85
Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology (2014) 0.84
Ovarian cancer: genomic analysis. Ann Oncol (2013) 0.84
Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. PLoS One (2012) 0.83
High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One (2013) 0.82
Knowledge-driven genomic interactions: an application in ovarian cancer. BioData Min (2014) 0.82
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. Br J Cancer (2009) 0.81
Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction. Methods (2014) 0.81
Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules (2016) 0.80
Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease. BMC Cancer (2012) 0.80
Somatic mutations favorable to patient survival are predominant in ovarian carcinomas. PLoS One (2014) 0.78
Novel biomarkers in type 1 diabetes. Rev Diabet Stud (2012) 0.78
Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines. Front Oncol (2014) 0.77
Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. Int Sch Res Notices (2014) 0.77
Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. Mt Sinai J Med (2009) 0.77
Improved microarray-based decision support with graph encoded interactome data. PLoS One (2010) 0.77
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. Gynecol Oncol (2015) 0.76
A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study. BMC Genomics (2012) 0.76
Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression. Genes Cancer (2014) 0.76
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract (2015) 0.76
KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer. Oncotarget (2016) 0.75
Yin Yang-1 increases apoptosis through Bax activation in pancreatic cancer cells. Oncotarget (2016) 0.75
Subcellular localization of APMCF1 and its biological significance of expression pattern in normal and malignant human tissues. J Exp Clin Cancer Res (2009) 0.75
The transcriptomic profile of ovarian cancer grading. Cancer Med (2014) 0.75
Clinicians' expectations for gene-driven cancer therapy. Clin Med Insights Oncol (2014) 0.75
Imputing Gene Expression to Maximize Platform Compatibility. Bioinformatics (2016) 0.75
A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma. Oncotarget (2016) 0.75
Structured Matrix Completion with Applications to Genomic Data Integration. J Am Stat Assoc (2016) 0.75
Novel risk models for early detection and screening of ovarian cancer. Oncotarget (2016) 0.75
Gynecologic biopsy for molecular profiling: a review for the interventional radiologist. Semin Intervent Radiol (2013) 0.75
Involvement of AF1q/MLLT11 in the progression of ovarian cancer. Oncotarget (2017) 0.75
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget (2017) 0.75
Molecular genetics complexity impeding research progress in breast and ovarian cancers. Mol Clin Oncol (2017) 0.75
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet (2007) 5.17
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol (2009) 3.38
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Global control of cell-cycle transcription by coupled CDK and network oscillators. Nature (2008) 3.32
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
Statistical mixture modeling for cell subtype identification in flow cytometry. Cytometry A (2008) 3.06
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med (2008) 2.68
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat (2008) 2.55
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol (2002) 2.51
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol (2004) 2.49
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Understanding GPU Programming for Statistical Computation: Studies in Massively Parallel Massive Mixtures. J Comput Graph Stat (2010) 2.38
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Challenges in evaluating psychosocial interventions for Autistic Spectrum Disorders. J Autism Dev Disord (2005) 2.23
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
Inference for non-regular parameters in optimal dynamic treatment regimes. Stat Methods Med Res (2009) 2.21
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Gender-specific methylation differences in relation to prenatal exposure to cigarette smoke. Gene (2011) 2.03
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res (2003) 1.99
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet (2011) 1.90
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy. Proc Natl Acad Sci U S A (2007) 1.82
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res (2005) 1.82
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80